Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Hedges Its Bet On Alzheimer’s With Eisai Tie-Up

This article was originally published in The Pink Sheet Daily

Executive Summary

The big biotech and the Japanese pharma are teaming up to develop four Alzheimer’s treatments in a collaboration that will split development costs and share profits.

Advertisement

Related Content

In Alzheimer’s, There’s A Lot Of Room Under The Radar
Eisai’s Bayesian Alzheimer’s Trial Aims For Quick Proof Of Concept With Fewer Subjects, Lower Cost
Lilly Ends Trial Of BACE Inhibitor For Alzheimer’s, But Says Class-Wide Safety Effect Unlikely

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS077045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel